These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 24766140)

  • 1. Incretin-modulated beta cell energetics in intact islets of Langerhans.
    Hodson DJ; Tarasov AI; Gimeno Brias S; Mitchell RK; Johnston NR; Haghollahi S; Cane MC; Bugliani M; Marchetti P; Bosco D; Johnson PR; Hughes SJ; Rutter GA
    Mol Endocrinol; 2014 Jun; 28(6):860-71. PubMed ID: 24766140
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pancreatic GLP-1 receptor activation is sufficient for incretin control of glucose metabolism in mice.
    Lamont BJ; Li Y; Kwan E; Brown TJ; Gaisano H; Drucker DJ
    J Clin Invest; 2012 Jan; 122(1):388-402. PubMed ID: 22182839
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lipotoxicity disrupts incretin-regulated human β cell connectivity.
    Hodson DJ; Mitchell RK; Bellomo EA; Sun G; Vinet L; Meda P; Li D; Li WH; Bugliani M; Marchetti P; Bosco D; Piemonti L; Johnson P; Hughes SJ; Rutter GA
    J Clin Invest; 2013 Oct; 123(10):4182-94. PubMed ID: 24018562
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Incretins: their physiology and application in the treatment of diabetes mellitus.
    Tasyurek HM; Altunbas HA; Balci MK; Sanlioglu S
    Diabetes Metab Res Rev; 2014 Jul; 30(5):354-71. PubMed ID: 24989141
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adenylyl cyclase 8 is central to glucagon-like peptide 1 signalling and effects of chronically elevated glucose in rat and human pancreatic beta cells.
    Roger B; Papin J; Vacher P; Raoux M; Mulot A; Dubois M; Kerr-Conte J; Voy BH; Pattou F; Charpentier G; Jonas JC; Moustaïd-Moussa N; Lang J
    Diabetologia; 2011 Feb; 54(2):390-402. PubMed ID: 21046358
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Epac2-dependent rap1 activation and the control of islet insulin secretion by glucagon-like peptide-1.
    Leech CA; Chepurny OG; Holz GG
    Vitam Horm; 2010; 84():279-302. PubMed ID: 21094904
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Incretins and Their Endocrine and Metabolic Functions.
    Seufert J
    Endocr Dev; 2017; 32():38-48. PubMed ID: 28873383
    [TBL] [Abstract][Full Text] [Related]  

  • 8. SUMO downregulates GLP-1-stimulated cAMP generation and insulin secretion.
    Rajan S; Torres J; Thompson MS; Philipson LH
    Am J Physiol Endocrinol Metab; 2012 Mar; 302(6):E714-23. PubMed ID: 22234371
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacological reduction of NEFA restores the efficacy of incretin-based therapies through GLP-1 receptor signalling in the beta cell in mouse models of diabetes.
    Kang ZF; Deng Y; Zhou Y; Fan RR; Chan JC; Laybutt DR; Luzuriaga J; Xu G
    Diabetologia; 2013 Feb; 56(2):423-33. PubMed ID: 23188390
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mouse pancreatic beta-cells exhibit preserved glucose competence after disruption of the glucagon-like peptide-1 receptor gene.
    Flamez D; Van Breusegem A; Scrocchi LA; Quartier E; Pipeleers D; Drucker DJ; Schuit F
    Diabetes; 1998 Apr; 47(4):646-52. PubMed ID: 9568699
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [The physiology of glucagon-like peptide-1 and its role in the pathophysiology of type 2 diabetes mellitus].
    Escalada FJ
    Med Clin (Barc); 2014 Sep; 143 Suppl 2():2-7. PubMed ID: 25437458
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The incretin system and its role in type 2 diabetes mellitus.
    Holst JJ; Vilsbøll T; Deacon CF
    Mol Cell Endocrinol; 2009 Jan; 297(1-2):127-36. PubMed ID: 18786605
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anti-diabetic actions of glucagon-like peptide-1 on pancreatic beta-cells.
    Lee YS; Jun HS
    Metabolism; 2014 Jan; 63(1):9-19. PubMed ID: 24140094
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Incretin and bone].
    Yamada Y
    Clin Calcium; 2009 Sep; 19(9):1312-7. PubMed ID: 19721203
    [TBL] [Abstract][Full Text] [Related]  

  • 15. GIP and GLP-1 as incretin hormones: lessons from single and double incretin receptor knockout mice.
    Hansotia T; Drucker DJ
    Regul Pept; 2005 Jun; 128(2):125-34. PubMed ID: 15780432
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Glucagon Potentiates Insulin Secretion Via β-Cell GCGR at Physiological Concentrations of Glucose.
    Zhang Y; Han C; Zhu W; Yang G; Peng X; Mehta S; Zhang J; Chen L; Liu Y
    Cells; 2021 Sep; 10(9):. PubMed ID: 34572144
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel extrapancreatic effects of incretin.
    Yamada Y; Tsukiyama K; Sato T; Shimizu T; Fujita H; Narita T
    J Diabetes Investig; 2016 Apr; 7 Suppl 1(Suppl 1):76-9. PubMed ID: 27186360
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Decreased TCF7L2 protein levels in type 2 diabetes mellitus correlate with downregulation of GIP- and GLP-1 receptors and impaired beta-cell function.
    Shu L; Matveyenko AV; Kerr-Conte J; Cho JH; McIntosh CH; Maedler K
    Hum Mol Genet; 2009 Jul; 18(13):2388-99. PubMed ID: 19386626
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Incretin therapies: highlighting common features and differences in the modes of action of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors.
    Nauck M
    Diabetes Obes Metab; 2016 Mar; 18(3):203-16. PubMed ID: 26489970
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Molecular mechanism of insulin secretion facilitated by incretin].
    Fujita Y; Haneda M
    Nihon Rinsho; 2011 May; 69(5):808-12. PubMed ID: 21595263
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.